Pfizer has announced a $35 per month cap on all of its insulin products for all patients regardless of insurance status, joining Eli Lilly and Novo Nordisk in making the life-saving medication affordable.
Impact
With all three major insulin manufacturers now capping prices at $35, the average diabetic patient will save $3,000-5,000 annually. The move effectively ends the insulin pricing crisis that forced millions to ration their medication.
Why Now
Congressional pressure, public outrage, and the threat of government price controls pushed pharmaceutical companies to act voluntarily. The Inflation Reduction Act's Medicare caps accelerated the industry-wide shift.
- $35/month cap on all Pfizer insulin
- All 3 major manufacturers now at $35
- $3,000-5,000 annual savings per patient
- No insurance requirement
